UroStream

In recent years, the treatment landscape for urothelial carcinoma (UC) has entered the era of precision medicine, with emerging therapeutic strategies offering new hope for patients. At the recent China Clinical Oncology Annual Advances Symposium (BOC) and Best of CSCO 2026 China, experts highlighted China's most significant original oncology achievements of the year and reviewed major advances in precision oncology across multiple tumor types, including genitourinary cancers, further advancing standardized cancer care in China.

As the prevalence of kidney stones continues to rise and complex stone disease becomes increasingly common, there is growing demand for minimally invasive, effective, and safe treatment strategies. Flexible ureteroscopy has become a cornerstone of upper urinary tract stone management; however, its role in treating large stone burdens, infection-related stones, and anatomically complex cases remains a subject of debate. Meanwhile, advances such as laser lithotripsy, single-use ureteroscopes, and suction-assisted access sheaths continue to expand treatment possibilities. Balancing maximal stone clearance with minimal complications remains one of the key challenges in modern endourology.

Transurethral resection of bladder tumor (TURBT) remains the standard treatment for non-muscle-invasive bladder cancer (NMIBC). However, up to 45% of patients experience tumor recurrence within one year following TURBT alone. Although intravesical therapies—including cytotoxic agents and immunotherapy—are widely used, substantial unmet clinical needs remain, underscoring the need for more effective treatment strategies.

The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting once again brought together the latest advances in cancer research from around the world. Among the most closely watched areas was radioligand therapy (RLT) for prostate cancer. During the meeting, the ProstACT Global 3 study team presented the first Part 1 results from its Phase III trial, focusing on the safety and dosimetry of TLX591 (¹⁷⁷Lu-rosopatamab tetraxetan). These findings provide early evidence supporting the feasibility of integrating TLX591 with standard-of-care treatment for patients with metastatic castration-resistant prostate cancer (mCRPC), while also demonstrating encouraging preliminary efficacy signals.

During the 2nd Peking University Urology Forum and the celebration of the 80th anniversary of the Department of Urology at Peking University First Hospital, Oncology Frontier – UroStream interviewed Prof. Weiren Huang from the Department of Urology, First Affiliated Hospital of Shenzhen University (Shenzhen Second People’s Hospital).

Chinese-developed immune checkpoint inhibitors, represented by toripalimab, are accelerating the transition of innovative therapies in urologic oncology from followers to global contributors. At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Chinese innovation was not only featured in oral presentations but also prominently showcased in the poster halls. Toripalimab combined with 9MW2821 demonstrated promising bladder-preservation potential after moving from advanced disease into the perioperative setting. Immunotherapy plus chemotherapy expanded a uniquely Chinese approach to bladder preservation. Meanwhile, a phase III neoadjuvant trial of toripalimab combined with axitinib in renal cell carcinoma marked the first randomized evaluation of a targeted-immunotherapy combination moving from the frontline setting into neoadjuvant treatment. In this issue, Oncology Frontier invited Professor Yijun Shen from Fudan University Shanghai Cancer Center to discuss key poster presentations and share his perspectives on the evolving landscape of immunotherapy in urologic oncology at this year's ASCO meeting.

From June 3 to 5, 2026, the Challenges in Laparoscopy, Robotics & AI 2026 (CILR-AI 2026) conference was held in Rome, Italy, bringing together leading experts from Europe, North America, Asia, and beyond.

The 2026 ASCO Annual Meeting has officially opened, bringing a wealth of landmark studies in genitourinary oncology and providing new momentum for precision treatment in urothelial carcinoma (UC). To promote standardized and precision-based management of urologic cancers in China, the Hainan Lecheng Hongyuan Medical Technology Innovation and Development Research Institute launched the “Academic Exchange Program on Precision Diagnosis and Treatment of Urologic Tumors,” bringing together leading experts to interpret the latest advances.

The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting has once again brought together the latest breakthroughs in cancer research and drug development from around the world. As the largest and most influential oncology conference globally, every oral presentation represents a major advance in clinical practice and translational research.

Although radical cystectomy remains the standard treatment for muscle-invasive bladder cancer (MIBC) and high-risk non-muscle-invasive bladder cancer (NMIBC) that is unresponsive to Bacillus Calmette-Guérin (BCG) therapy, many patients are either unsuitable for or unwilling to undergo radical cystectomy because of underlying comorbidities and the potential impact on quality of life. Consequently, there is an urgent need to explore novel treatment approaches. At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, a study conducted by the team of Professor Wang He and Professor Wenlong Zhong from Sun Yat-sen Memorial Hospital, Sun Yat-sen University, was selected for presentation. The study evaluated a bladder-preservation strategy combining disitamab vedotin-based systemic targeted immunotherapy with transurethral resection of bladder tumor (TURBT) and pelvic lymph node dissection (PLND), offering a new possibility for bladder preservation in patients with MIBC. Oncology Frontier – UroStream invited both experts to discuss the clinical value, efficacy, and future prospects of this innovative approach.